Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study
Annals of Neurology · 2026-10 · 100 (4) · 788-792
DOI: 10.1002/ana.78286 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Neurology, online erschienen am 17.06.2026. Verfasst von Thomas Frisell und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Rituximab, Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies (DMTs) between 2014 and 2025. Infection outcomes included serious infections, hospital‐diagnosed infections, and antibiotic use, and relapse risk was assessed as a marker of efficacy. Both rituximab and ocrelizumab were associated with higher infection rates than other DMTs, while relapse rates were substantially lower. Infection and relapse risks were similar between rituximab and ocrelizumab. ANN NEUROL 2026;100:788–792
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Academic Specialist Clinic, SLSO and Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Thomas Frisell, Fredrik Piehl
Zitieren
APA
Frisell, T., Hedberg, S., & Piehl, F. (2026). Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Annals of Neurology, 100(4), 788-792. https://doi.org/10.1002/ana.78286
Vancouver
Frisell T, Hedberg S, Piehl F. Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Annals of Neurology. 2026;100(4):788-792. doi:10.1002/ana.78286
BibTeX
@article{Frisell2026,
author = {Frisell, Thomas and Hedberg, Sebastian and Piehl, Fredrik},
title = {Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study},
journal = {Annals of Neurology},
year = {2026},
volume = {100},
number = {4},
pages = {788--792},
doi = {10.1002/ana.78286}
}
EUVIMED